Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab device study in healthy subjects
NCT03886948Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2019
- Primary completion
- Oct 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mirikizumab in ulcerative colitis (UC) and Crohn's disease (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Observed Drug Concentration at Day 85, Area Under the Concentration Versus Time Curve From Time Zero to Time t at Day 85 and 2 more. Started Mar 2019; status: completed.
02
Drugs
mirikizumab
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT03886948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03886948.